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ABSTRACT
The study of hematopoietic stem cells (HSCs) and the process
by which they differentiate into committed progenitors has
been hampered by the lack of in vitro clonal assays that can
support erythroid, myeloid and lymphoid differentiation. We
describe a method for the isolation from human fetal liver of
highly purified candidate HSCs and progenitors based on the
phenotypes CD38
-CD34
++ and CD38
+CD34
++, respectively.
We also describe a method for the growth of colony-forming
cells (CFCs) from these cell populations, under defined culture
conditions, that supports the differentiation of erythroid,
CD14/CD15
+ myeloid, CD1a
+ dendritic cell and CD56
+ NK
cell lineages. Flow cytometric analyses of individual colonies
demonstrate that CFCs with erythroid, myeloid and lymphoid
potential are distributed among both the CD38
- and CD38
+
populations of CD34
++ progenitors.
INTRODUCTION
Maintenance of blood cell homeostasis involves the daily
production of a tremendous number of blood cells from a
relatively small pool of stem cells. Regulation of hematopoiesis
is complex involving both hormonal and local regulatory
mechanisms that can promote or inhibit the growth and
differentiation of stem cells into progenitors and, in turn,
mature blood cells. In adult mammals, hematopoiesis occurs
primarily in the bone marrow. However, hematopoiesis can
occur in other locations as well such as in the thymus, which is
specialized in the generation of T cells. In addition, small
numbers of natural killer (NK) cells, B cells, dendritic cells
(DCs) and myeloid cells are also generated in the thymus (1,2).
The spleen offers another potential site for hematopoiesis,
especially in small animals. Hematopoietic progenitors have
also been found in the adult liver (3) .
Hematopoietic progenitors and stem cells are distributed
continually to favorable sites of hematopoiesis. This is
evidenced by the presence of a small number of these cells that
can be found circulating in the peripheral blood (4). The
numbers of circulating progenitors and stem cells can increase
dramatically when hematopoietic activity is increased.
Treatment with various hematopoietic growth factors or
recovery from chemotherapeutic injury can result in the
mobilization of hematopoietic progenitors and stem cells (5).
This is reminiscent of mammalian development, a period of
rapid growth in hematopoietic tissues marked by high levels of
circulating progenitors and stem cells and a remarkable series
of transitions between hematopoietic tissues (6,7).
Hematopoiesis begins extraembryonically in the blood islands
of the yolk sac (6). Intraembryonic hematopoiesis is first
observed in the paraaortic splanchnopleura or aorta-gonad-
mesonephros region and moves to the liver, the primary site of
hematopoiesis during much of fetal life (7). In mice,
hematopoiesis transitions from the liver to the spleen in the
older fetus, and then to the bone marrow around the time of
birth. In humans, the relocation of hematopoiesis from the liver
to the bone marrow begins early in the second trimester and the
spleen is never a significant location for hematopoiesis (8).
A large number of culture systems have been developed for the
study of hematopoiesis in vitro. One such system that has been
prominent in much of the research in this field is the colony-
forming cell (CFC) or colony-forming unit-culture (CFU-C)
assay (9,10). In its basic form, the CFC assay is a clonal assay
used for the enumeration of hematopoietic progenitors.
Progenitors are suspended in a combination of culture medium,
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growth factors and a semi-solid matrix such as methylcellulose
or agarose. Over time the suspended progenitors proliferate and
differentiate forming a colony of blood cells that can be readily
counted using an inverted or dissecting microscope. The CFC
assay has evolved since its beginnings in the mid 1960's.
Layers of feeder cells, a source of growth factors, were
replaced by conditioned media and eventually recombinant
cytokines, discovered in part through the use of the CFC assay.
There is also no longer a need for serum in the culture medium
as various formulations of defined serum components have
been devised that can substitute serum (11,12).
Stem cells are defined by their extensive proliferative capacity,
including a limited ability for self-renewal, and their
pluripotentiality. Although no CFC assay has ever been
developed that can definitively detect stem cells, CFC assays
have been developed to measure the properties of extensive
proliferative capacity and pluripotentiality. High-proliferative
potential CFCs (HPP-CFCs) are a primitive subpopulation of
progenitors, likely including stem cells, that are characterized
by their ability to form large colonies containing 1 x 10
4 cells
(13). HPP-CFCs were first detected when two sources of
conditioned media were combined to provide a synergistic
combination of cytokines that supported the growth of
primitive progenitors, a characteristic requirement of primitive
progenitors. The blast cell colony assay, similar to the HPP-
CFC assay, is another variant of the CFC assay that detects
cells with an extensive proliferative capacity based, in part, on
their potential to generate secondary colonies when replated
(14). The conditions that support the generation of myeloid and
erythroid cells from CFCs were developed early in the
evolution of the CFC assay. However, growth of lymphoid
progenitors and multipotent progenitors with lymphoid
potential hasn't been possible until more recently. With the
discovery of the cytokines interleukin (IL)-7 and IL-15, the
clonal growth of murine B cell progenitors (15-17) and NK-
cell progenitors (18) was achieved. Indeed, murine multipotent
CFCs can form colonies with myeloid, erythroid and lymphoid
cells (19,20). Similar successes with human lymphoid and
multipotent CFCs have trailed the murine results. Initially,
human NK-cell colonies were grown from committed
lymphoid CFCs isolated from thymic tissue (21). Recently, our
laboratory reported the growth of CFCs with erythroid,
myeloid, DC and NK cell potential (22). These CFCs were
isolated from human fetal liver tissues, grown and detected by
the methods detailed in this report.
MATERIALS AND METHODS
Human fetal liver progenitors
Livers were harvested from midgestation fetuses obtained with
maternal consent from elective abortions. Research with fetal
tissue was performed with approval of the Committee of
Human Research at our institute. Two subpopulations of
progenitors were isolated by the method detailed in the
Protocol section: CD38
-CD34
++lineage- (lineage or Lin = CD3,
CD14, CD19, CD20, CD56 and CD235a) and
CD38
+CD34
++Lin
- fetal liver cells (23). For simplicity, these
two populations of cells will be referred to as CD38
- and
CD38
+ progenitors. The CD38
- population is enriched in
hematopoietic stem cells whereas the CD38
+ population is an
intermediate population of progenitors that still expresses high
levels of CD34 and is believed to be derived from the CD38
-
stem cells (23,24).
Colony-forming cell assay
A detailed description of the culture conditions used to grow
multipotent CFC is given in the Protocol section. Briefly, 50 to
100 cells were plated/culture dish and 3 to 8 dishes were
analyzed for each experiment. Progenitors were grown in semi-
solid medium under serum-deprived conditions supplemented
with six recombinant human cytokines: kit ligand (KL), flk-
2/flt-3 ligand (FL), GM-CSF, thrombopoietin (TPO),
erythropoietin (EPO) and interleukin-15 (IL-15). KL, FL, TPO
and IL-15 were purchased from R&D Systems, Inc.
(Minneapolis, MN, http://www.rndsystems.com). EPO was
purchased from Amgen (Thousand Oaks, CA,
http://www.amgen.com and GM-CSF (Leukine) from
Immunex Corporation (Seattle, WA,
http://www.immunex.com). The serum-deprived medium used
has been shown to be superior to serum-replete medium in
supporting the growth of myeloid and erythroid cells (25,26).
The cytokines used were chosen based on previous
experiments that indicated that the combination KL+FL+GM-
CSF+IL-15 supports the generation NK cells from CD38
-
progenitors (27). Furthermore, GM-CSF, FL, KL and IL-15
have also been shown to support the growth of DCs (28-30).
EPO and ML were further added to the cultures to support
erythroid and megakaryocytic development, which did not
appear to interfere with the development of the myeloid,
dendritic and NK cells (22). CFCs were cultured for 3 weeks
and analyzed for lineage composition.
Analyses of colony lineage composition
Colonies containing erythrocytes were identified visually by
the presence of hemoglobinized cells. The presence of myeloid
(CD14
+ and/or CD15
+ cells) and NK cells (CD56
+ cells) was
determined by flow cytometric analyses of live cells isolated
from individually plucked colonies. Anti-CD14-PE (clone
TüK4) (Caltag Laboratories, Burlingame, CA,
http://www.caltag.com), anti-CD15-PE (clone VIMC6) (Caltag
Laboratories) and anti-CD56-FITC (clone C5.9) (Exalpha
Corporation, Boston, MA, http://www.exalpha.com) were the
monoclonal antibodies (mAbs) used to stain the colonies. In
some experiments, anti-CD1a-PE (clone T6) (Beckman
Coulter, Inc., Miami, FL, http://www.beckmancoulter.com)
was used to detect DCs combined with anti-CD14-APC (clone
M5E2) (BD Biosciences, http://www.bdbiosciences.com), anti-
CD15-APC (clone HI98) (BD Biosciences) and anti-CD56-
FITC. A detailed protocol for the analysis of colony lineage
composition is presented in the Protocol section. A FACScan
or FACSCalibur flow cytometer (BD Biosciences) was used to
analyze the stained colonies.Muench et al.
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RESULTS AND DISCUSSION
The early stages of lymphoid development are only partially
characterized. Most schema depicting hematopoietic
differentiation place the separation of lymphoid progenitors
from myeloid-erythroid progenitors as the first major branch
point in hematopoiesis. This early division of lymphopoiesis
from myeloerythropoiesis does have some basis in
experimental observation. Galy et al. isolated a CD10
+CD38
+
committed lymphoid progenitor from among early
hematopoietic progenitors that express high levels of CD34
(31). These lymphoid progenitors were capable of generating T
cells, B cells, NK cells and DCs. Since there is abundant
evidence that stem cells reside among CD38
-CD34
++ cells (24),
a model in which pluripotent CD38
- stem cells differentiate
into multipotent CD38
+ lymphoid and myeloerythroid
progenitors can be envisioned.
To further research the development of lymphoid progenitors,
we set out to define in vitro conditions for the clonal growth of
progenitors with lymphoid, myeloid and erythroid potential.
Two cell populations expressing high levels of CD34 were
studied, CD38
- candidate stem cells and CD38
+ progenitors.
These cells were isolated from human fetal liver according to
the criteria depicted in Fig. 1. Cells were isolated based on
their lack of staining with PI (Fig. 1A), low side-light scatter
(Fig. 1B) and lack of expression of a panel of Lin markers (Fig.
1C). Cells were sorted using regions similar to the ones shown
in Fig. 1D. These regions are drawn conservatively since
analyses of the sorted cells (Fig. 1E and F) always indicate that
the sorted cells have spread beyond the original regions used to
sort the cells. Nonetheless, highly purified populations of
progenitors and candidate stem cells can be obtained. These
cells were cultured under serum-deprived conditions using a
methylcellulose-based colony assay system. The cytokine
cocktail KL+FL+TPO+GM-CSF+EPO+IL-15 was used, which
supported the growth of erythroid, myeloid, NK cells and DCs.
Currently, conditions that support the development of human
B- and T-cells in colony assays remain elusive, although B
cells have been generated under defined liquid culture
conditions (27). We speculate that the efficiency of B-cell
formation remains below the threshold for detection of these
cells within individual colonies (22).
Colonies grown from the two cell populations were scored
using a dissecting microscope. To better insure clonality we
have settled on plating only 50 sorted cells/plate and analyzing
up to 8 dishes for each cell population. At this starting density
we obtained an average 9.5 and 11 colonies/dish for CD38
- and
CD38
+ progenitors, respectively (22). Even at these low
densities colonies were sometimes closely spaced or
overlapping. However, we have had little difficulty in
harvesting these colonies by omitting to harvest portions of the
colony that may be contaminated with another colony's cells.
Before harvest, the estimated size and the presence or absence
of hemoglobinized erythrocytes was recorded as each colony
was visualized. Examples of myeloid colonies are shown in
Figs. 2A and 2B and representative myeloerythroid colonies
are shown in Figs. 2C-F. After recording the attributes of a
colony, the colony was drawn into a 200µl pipette tip (Figs.
2D-F) and dispersed in a solution of blocking buffer and mAbs.
Fig. 1: Isolation of primitive hematopoietic progenitors
from human fetal liver. Hematopoietic progenitors were
isolated by FACS following enrichment by two rounds of
immunomagnetic bead depletion of Lin
+ cells and isolation of
light-density cells. Dead cells and debris are removed using a
region (A, R1) drawn to include PI
- events with a moderate
forward scatter. Cells with a low to medium side scatter are
then selected using a second region (B, R2). Any remaining
Lin-FITC
+ cells are then removed with a third region (R3) as
shown in C. Expression of CD34 and CD38 are then viewed on
events gated to fall within regions 1-3 (D). CD38
+CD34
++ and
CD38
-CD34
++ events are selected using regions 4 and 5,
respectively, as indicated. These regions are drawn
conservatively as analysis of the sorted cells (E and F) usually
indicates some slight spread of the populations outside the sort
regions. Ideally, the isolated CD38
+ and CD38
- progenitors will
be nearly contiguous, but non-overlapping, populations.
After staining, individual colonies were analyzed by flow
cytometry (Fig. 3). Live and dead cells were distinguished
using PI. Considerable numbers of dead cells and debris were
removed from analysis using a gate similar to the one shown in
Fig. 1A. As shown in Fig. 3, cell populations were observedMuench et al.
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with different light scatter properties (22). Erythrocytes, NK
cells and a subpopulation of the CD14
+ and CD15
+ cells had a
low side scatter profile (Fig. 3A, blue events). Most cells with a
high side scatter had a high autofluorescence and many also
expressed CD14 (Fig. 3, red events). These high side scatter
cells represent primarily DCs as discussed below.
Fig. 2: Colony formation by CD38
- progenitors. Examples of
myeloid colonies are shown in A and B. Mixed lineage
colonies, derived from HPP-CFCs, containing myeloid and
erythroid cells are shown in C and D. Harvest, using a
micropipette, of one of the colonies shown in D is shown in E.
The small number of cells remaining after the harvest of the
colony is shown in F. All colonies were grown in
KL+FL+ML+GM-CSF+EPO+IL-15. Colonies were viewed on
a 2mm grid.
We analyzed 313 colonies grown from CD38
- progenitors (n =
5 experiments) and 110 colonies grown from CD38
+
progenitors (n = 4 experiments) (22). Progenitors capable of
giving rise to myeloid, erythroid and NK cells were enriched
among the CD38
- fraction, representing 13.7% of all CFC
compared to 2.7% among all CD38
+ CFCs. These results are
consistent with the belief that stem cells reside among the
CD38
- progenitors, in that multipotent progenitors were
enriched among the CD38
- population. Nonetheless, the
majority (51.8%) of CD38
- CFCs formed colonies containing
only myeloid cells. Another 21.7% had both myeloid and
erythroid cells, but no identifiable NK cells. Similarly, pure
myeloid (40.0%) and myeloerythroid (39.1%) colonies
represented the bulk of CD38
+ CFCs. A small (5.5%)
subpopulation of CD38
+ CFCs generated erythroid colonies
with no identifiable myeloid cells. Such erythroid colonies
represented <1% of CD38
- CFCs.
Except for a single colony derived from CD38
+ CFCs, no pure
NK-cell colonies were observed. It should be noted that even
this one NK-cell colony contained a number of cells that failed
to stain with either the CD14/CD15 or the CD56 mAbs. Not all
cells mature in each colony at the same rate. Consequently, our
detection methods may fail to ascertain the complete lineage
composition of all colonies, especially in small colonies.
Analysis of the colonies after 3 weeks of growth represents a
compromise between earlier time points at which fewer cells
express CD14 or begin to be hemoglobinized and later time
points when cells begin to die and the cultures decline (26,32).
Presently, we have not had success in expanding the mature
NK cells generated in vitro, although the NK cells are
functionally mature and capable of killing appropriate target
cells (27). In liquid cultures the number of NK cells relative to
the numbers of myeloid and erythroid cells is low (generally
<5%). Likewise, a mean of only 24.9 CD56
+ cells were
detected/colony (22). This low number of NK cells required the
threshold for detection to be set to a low of 3 events above
background staining. Nonspecific binding of the FITC-
conjugated IgG2b antibody was very low to non-existent
enabling detection of low numbers of CD56-FITC
+ cells,
Fig. 3: Determination of lineage content of individual
colonies by flow cytometry. Results of three colonies
differing in their lineage composition are shown. Low side
scatter cells are shown in blue and high side scatter cells are
shown in red as indicated in A. A colony containing
myelocytes and erythrocytes, but no NK cells, is shown in B.
Note the two populations of cells CD14/CD15
+ cells have
distinctive side scatter profiles. A multilineage colony
containing erythrocytes, myelocytes, NK cells and most likely
CD14
+ DCs is shown in C. A colony containing mostly
CD14
+ DCs and NK cells is shown in D. All colonies were
derived from CD38
- progenitors (22).Muench et al.
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whereas PE-conjugated mAbs have slightly higher background
staining. NK cells were defined as not only CD56
+ events but
also as cells with a low side scatter (Fig. 3), which further
reduces the chances of false positives. As culture conditions for
the growth of lymphocytes improve we anticipate greater
numbers of NK-cell colonies to be detected and the detection
of CFCs with B-cell potential to become feasible.
Since a high proliferative capacity is another property of stem
cells, we also analyzed the fraction of colonies that grew from
HPP-CFCs. HPP-CFCs represented 16.4% of the CD38
- CFCs
and 22.0% of the CD38
+ CFCs (22). Nearly all of these
colonies contained both myeloid and erythroid cells. It should
be noted that support of the erythroid lineage in our cultures
increased the numbers of HPP-CFCs observed over the number
observed in the absence of EPO. This is because the presence
of erythrocytes in a colony greatly increases the size of the
colony. For instance, HPP-CFCs are restricted to the CD34
++
fraction of fetal liver cells when only myelopoiesis is supported
(33), whereas further support of erythropoiesis results in
colonies with over 1 x 10
4 cells arising from even the more
mature CD34
+Lin
- population of fetal liver cells (26). When
analyzed by flow cytometry, 59.4% of CD38
- HPP-CFC
generated colonies containing erythroid, myeloid and NK cells,
whereas 46.3% of CD38
+ HPP-CFC generated such colonies
(22). Therefore, this analysis further suggested an enrichment
of stem cells among the CD38
- fraction, but the high frequency
of multipotent HPP-CFC among CD38
+ progenitors was
unexpected. We initially held out the possibility that the
presence of multilineage HPP-CFCs among the CD38
+ fraction
of progenitors suggests that rare stem cells may also reside
among this fraction of fetal liver cells (22). However, recent
analysis of the bone marrow reconstituting ability in
NOD/SCID mice of CD38
-CD34
++/+ and CD38
+CD34
++/+
progenitors, isolated from umbilical cord blood, showed that
long-term reconstituting ability was limited to the CD38
-
fraction (34). We have also subsequently tested the
reconstituting potential of the two fractions of fetal liver
progenitors and found that only the CD38
- fraction of
progenitors could generate active hematopoiesis in the bone
marrow of NOD/SCID mice 8 weeks after transplantation
(authors unpublished observations). Thus, it appears that the
CD38
+ CFCs with myeloid, erythroid and lymphoid potential
represent a population of multipotent progenitors rather than
stem cells.
Further analysis of the two subpopulations of CD14/CD15
+
cells present in the hematopoietic colonies (Fig. 3) indicated
that the high side-scatter cells were CD14
+ DCs (22). These
cells were identified as myeloid DCs (DC1) based on their
expression of CD2, CD4, CD11a, CD11c, CD40, CD80, CD83,
CD86, HLA-DR and HLA-DQ (35-37). Not all high side
scatter cells expressed all of these markers, but the general
pattern suggested that many of the high side scatter cells
represented DCs at varying stages of differentiation. In
addition, the marker CD1a was found expressed on most of the
DCs generated under our culture conditions, further indicating
a myeloid origin for these cells (37).
CD1a
+ cells were found in approximately three-quarters of all
colonies grown from CD38
- and CD38
+ progenitors. Examples
of CD1a expression on cells isolated from representative
colonies are shown in Fig. 4. These colonies were stained with
anti-CD56-FITC, anti-CD1a-PE, anti-CD14-APC, anti-CD15-
APC and PI, enabling us to distinguish non-DC myeloid cells
from DCs.
Fig. 4: Flow cytometric analysis of myelocyte and DC
content in individual colonies. Results of five colonies
differing in their lineage composition are shown. Low side
scatter cells are shown in blue and high side scatter cells are
shown in red as indicated in A. A colony with myeloid cells
but no CD1a
+ DCs is shown in B. C-E show colonies with
varying frequencies of CD1a
+ and CD14/CD15
+ cells. F is an
example of a colony primarily composed of CD1a
+ DCs. All
colonies shown were derived from CD38
- progenitors.
The stained cells were analyzed on a two-laser FACSCalibur
flow cytometer. Colonies containing CD14/CD15
+ myeloid
cells, but no DCs, were observed such as shown in Fig. 4B.
Varying levels of myeloid and DCs were also observed as
exampled by Fig. 4C-E. Note that the expression of CD14 on
CD1a
+ cells was variable in these colonies (CD15 is not
expressed by the high side-scatter cells under these culture
conditions). Fig. 4F is an example of a colony containingMuench et al.
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primarily DCs and no myeloid cells. Thus, using the techniques
described the clonal analysis of CFCs capable of erythroid,
myeloid, DC and NK cell differentiation is feasible.
We anticipate that such analyses of the lineage potential of
CFCs will be useful in research aimed at understanding the
early events of hematopoiesis. Analyses of myeloerythroid
progenitors have indicated that hematopoietic differentiation is,
in large part, a stochastic process (38). Our analysis of lineage
potential of CD38
- and CD38
+ CFCs would agree with this
assessment. Differentiation, mostly a loss of erythroid
potential, was found to occur at the CD38
- stage of
differentiation whereas CD38
+ progenitors still contained many
multipotent progenitors. In regards to NK-lymphopoiesis in
particular, our data suggests that multiple pathways of
differentiation may exist. Recently, Hao et al. demonstrated the
existence of a lymphoid committed progenitor among the
CD38
- fraction (39). Thus, based on our work and that of Galy
et al. (31), the data suggest that segregation of the lymphoid
from the myeloid and erythroid pathways can occur either very
early in hematopoietic differentiation or later at the CD38
+
stage of differentiation. The possibility also exists for multiple
pathways of NK cell differentiation. A lymphoid pathway
arising from a common T-, B-, NK- and lymphoid dendritic-
cell may define one pathway for NK cell differentiation,
whereas a myeloid pathway for NK-cell differentiation may
also exist (22,37). Such a hypothesis would be consistent with
previous observations regarding the stochastic nature of
hematopoietic differentiation. Further analysis of the
multilineage potential among subsets of early hematopoietic
progenitors will help to understand the process of
hematopoietic differentiation and the environmental signals
that control it.
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PROTOCOLS
Protocol 1: Isolation of defined subsets of progenitors from human fetal liver
Reagents:
Cell Wash Buffer (PBS/BSA). The standard medium used to wash and hold cells in suspension during the isolation procedure
consists of phosphate buffered saline (PBS), without Ca
2+ and Mg
2+, containing 0.3% bovine serum albumin (BSA) (product
#100362; Roche Molecular Biochemicals, Indianapolis, IN, http://www.ibuyrmb.com) and 50µg/mL gentamicin sulfate (# 15750,
Life Technologies/Gibco BRL, http://www.lifetech.com). PBS/BSA is prepared by dissolving 3g BSA in 1L PBS and adding 1mL
of 50mg/mL gentamicin sulfate. The solution is sterilized by filtration (0.22µ) and stored at 4°C. PBS containing 2% fetal bovine
serum (FBS) can be used in place of PBS/BSA if the cells are not to be grown under defined culture conditions.
Blocking Buffer. PBS is supplemented with 0.01% NaN3 (Sigma Chemical Company; St. Louis, MO,
http://www.sigmaaldrich.com) and 5% normal mouse serum (Gemini Bio-Products, Woodland, CA, http://www.gembio.com). The
solution is filtered (0.22µ) to remove precipitates from the serum. Store at 4°C.
FACS Wash Buffer. This buffer is made by adding NaN3 at a final concentration of 0.01% to PBS/BSA. Store at 4°C.
FACS PI Buffer. This buffer is prepared by adding NaN3 to a final concentration of 0.01% and propidium iodide (Molecular
Probes, Eugene, OR, http://www.probes.com) to a final concentration of 2µg/ml to PBS/BSA. Store at 4°C.
Cell-dissociation cup. (Sigma Chemical Company, #CD-1) Use with a 50 or 60 mesh screen and glass pestle.
Disposable plasticware: 35 x 10mm tissue culture dish (Falcon, BD Bioscience), 100 x 20mm tissue culture dish (Falcon), 50ml
conical tubes (Falcon), T25 flask, 15mL polypropylene tube, 15mL polystyrene tubes, 12 x 75mm tubes (Falcon brand tubes are
highly recommended for flow cytometers manufactured by Becton Dickinson), 1.2mL microtiter tubes (#02-681-376, Fisher
Scientific, Pittsburgh, PA, http://www.fishersci.com).
0.4% Trypan blue. (#15250-061, Life Technologies)
Cell strainers. 40µm (#2340 Falcon), 70µm (#2350 Falcon) and 120µm (#2360 Falcon)
1.077g/mL Nycoprep. (#100-2368, Life Technologies)
BioMag goat anti-mouse IgG magnetic particles. (#84340, Polysciences, Inc., Warrington, PA, http://www.polysciences.com).
Wash the beads twice before use using PBS/BSA as recommended by the manufacturer. Suspend the washed beads in 10-20mL
PBS/BSA.
Sheep anti-mouse coated Dynabeads. (#110.02, Dynal Biotech Inc., Lake Success, NY, http://www.dynal.no)Muench et al.
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Monoclonal antibodies (mAb):
Table 1:
Specificity-Label Clone Product # Isotype Source
CD3-FITC
1 SK7 349201 IgG1 BD Biosciences, http://www.bdbiosciences.com
CD14-FITC
1 TüK4 MHCD1401 IgG2a Caltag Laboratories, http://www.caltag.com
CD19-FITC SJ25C1 340409 IgG1 BD Biosciences
CD20-FITC HI47 MHCD2001 IgG3 Caltag Laboratories
CD34-FITC 581 IM 1870 IgG1 Beckman-Coulter,
http://www.beckmancoulter.com
CD34-APC
1 581 IM2472 IgG1 Beckman-Coulter
CD38
-PE HB7 347687 IgG1 BD Biosciences
CD56-FITC C5.9 0562 IgG2b Exalpha Inc., http://www.exalpha.com
CD235a 10F7MN HB-8162 IgG1 ATCC
1, http://www.atcc.org
CD235a-FITC 11E4B-7-6 IM2212 IgG1 Beckman-Coulter Inc
None/FITC polyclonal MG101 IgG1 Caltag Laboratories
None/PE polyclonal MG104 IgG1 Caltag Laboratories
None/APC polyclonal IM 2475 IgG1 Beckman-Coulter Inc.
1Abbreviations: Fluorescein isothiocyanate (FITC), phycoerythrin (PE), allophycocyanin (APC), American Type
Culture Collection (ATCC).
Protocol:
1.  Fetal liver, obtained from elective abortion performed by cervical dilatation and extraction, is usually disrupted and
contaminated with microbes (40). Large pieces of liver tissue can most often be obtained, but they are rarely intact or
sterile. The gestational age of the abortuses is approximated from the foot-length of the fetus using standard nomograms
(41-43). The liver is transported to the laboratory in 50mL tubes in approximately 30mL PBS/BSA at 4°C. Alternatively,
the single antibiotic in the PBS/BSA solution can be substituted for a more potent combination of anti-microbial drugs
consisting of erythromycin lactobionate (100µg/mL), gentamicin sulfate (50µg/mL), vancomycin hydrochloride
(100µg/mL), and amphotericin B (2.5µg/mL) (25). Although unprocessed liver is most often contaminated, after
processing and cell sorting very few tissues show any evidence of microbial contamination (44). The liver is transported
on ice and, in our laboratory, processing begins within 6 hours after abortion.
2.  Wash the liver twice with 20mL of PBS/BSA and place the tissue in about 20mL of PBS/BSA into a cell-dissociation cup
resting on the bottom half of a 100 x 20mm petri dish. Press the liver through the screen using a glass pestle. In the
beginning, use vertical motions with the pestle as much as possible to avoid killing cells by shearing them across the
mesh. The cell suspension can be recycled through the mesh to help wash cells through. Collect the cell suspension and
place it in a new 50mL tube. Press the remaining fragments of liver through the mesh and wash with small volumes (7-
10ml) of PBS/BSA. Most specimens can be prepared in a final volume of 50ml (1 tube), unless the liver is particularly
large in which case 2 tubes can be used. The dissociation of the liver is finished when the majority of the red pulp has
been recovered leaving behind a white-colored tissue (biliary tree, ligament, etc). The number of viable cells is
determined using trypan blue exclusion and a hemocytometer. All live cells, including erythrocytes, are counted to
quantify the amount of mAb required for depletion of the red cells. In our experience, livers between the gestational ages
of 16 and 24 weeks contain a median 2 x 10
9 cells (range 3.9 x 10
8 to 1.1 x 10
10) (25).Muench et al.
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3.  Label the fetal erythrocytes using anti-CD235a mAb by incubating the cells with a saturating amount of mAb in the form
of culture supernatant from the 10F7MN cell line. Culture supernatant is used to reduce the cost of the procedure, but
commercially available unconjugated or FITC-labeled anti-CD235a mAb can be substituted. Incubate for 30 minutes on
ice. (The BioMag beads can be washed during this time, see step 5 below.)
4.  Pellet the cells by centrifugation (7 minutes at 300 X g at 4°C), remove the cloudy supernatant and suspend the cells in
50mL PBS/BSA. Wash the cells by centrifugation again and suspend the washed cells in 20mL of PBS/BSA. If a large
number of cell clumps have developed, the cells can be filtered using 120µm (or smaller) cell strainer. The liberal use of
cell strainers to remove clumps of cells is recommended throughout the isolation procedure. Hepatocytes and other cell
types are destroyed by the repeated centrifugation of the cells, leading to clumping of the dead and live cells.
5.  The labeled CD235a
+ cells are depleted using a 5:1 ratio of BioMag magnetic particles per cell. We have reduced the
number of particles recommended by the manufacturer to achieve a good level of depletion at a low cost. Add the liver
cell suspension to the washed beads in a 25cm
2 tissue culture flask. Mix and incubate on ice for 15 minutes. Mix the flask
several times during the incubation period. Place the flask against a magnet and allow the beads to be attracted towards
the magnet for at least 5 minutes. Remove the unbound liver cells and place into a 50mL tube. Without removing the flask
from the magnet, gently add 10-20mL of PBS/BSA to help rinse out the remaining unbound cells. Add the rinse volume
of PBS/BSA to the cells in the 50mL tube. The erythrocyte depletion is likely to be incomplete and the recovered cell
suspension may still appear dark red/brown in color. Most of the contaminating erythrocytes and magnetic beads are
depleted in the next step of the protocol.
6.  Pellet the cells by centrifugation (7 minutes at 300X g at 4°C). Suspend the pellet in 5mL of PBS/BSA. Filter using a 70
or 40µ mesh cell strainer if necessary. Slowly layer the cell suspension on top of 7mL of Nycoprep density medium in a
15mL polypropylene tube. Centrifuge for 25 minutes at 800X g at room temperature (20-25°C) with the brake off. Collect
the light density fraction and add these light density fetal liver (LDFL) cells to a 15mL tube. Discard the pelleted cells.
Fill the tube containing the LDFL with PBS/BSA, mix and centrifuge (7 minutes at 300X g at 4°C). Remove the
supernatant down to 0.1mL and add 0.9mL of blocking buffer. Count the number of live cells recovered (viability at this
stage should by high). Typically, 2-4 x 10
7 cells are recovered per tissue, but recovery may be higher if many immature
erythrocytes have escaped the depletion procedure. Place the cells on ice for several minutes. It is important to save an
aliquot of these cells for use as controls for setting up the flow cytometer (see step 11 below).
7.  Add saturating amounts of FITC-labeled mAbs for the depletion of mature blood cells and committed B-cell progenitors,
collectively called lineage
+ (Lin
+) cells:
Table 2:
Mab Specificity Cell Specificity Volume
CD3 T cells 20µL
CD14 Monocytes 10µL
CD19 B cells and B-cell progenitors 40µL
CD20 B cells and B-cell progenitors 20µL
CD56 NK cells and T cells 20µL
CD235a Erythrocytes 20µL
8.  Incubate on ice for 30 minutes or overnight (if cell sorting is to be performed the next day).
9.  Wash the cells twice with PBS/BSA (7 minutes at 300X g at 4°C). Suspend the cells in 2mL of PBS/BSA and mix with
Dynabeads at a ratio of 5 beads per cell in a 15mL polystyrene tube. Incubate for 15 minutes with constant mixing at 4°C.
Add PBS/BSA to a volume of 12mL. Place the tube next to a magnet and allow the particles to collect to the wall of the
tube for 2 minutes. Recover the unbound cells to a new 15mL tube and subject them to a second round of magnetic
depletion. Recover the unbound cells and concentrate by centrifugation (7 minutes at 300X g at 4°C). The pellet shouldMuench et al.
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contain very few, if any, visible erythrocytes. Suspend the cells in 1mL of blocking buffer, and determine the number of
live cells recovered. Typically, 1-2 x 10
7 Lin-LDFL cells are recovered per tissue.
10.  Lin-LDFL cells are stained with saturating amounts of anti-CD34-APC (100µl) and anti-CD38
-PE (100µl) for 30 minutes
on ice or overnight at 4°C.
11.  The cells are washed twice by centrifugation in PBS/BSA for 7 minutes at 300X g at 4°C. The washed cells are suspended
in 3-4mL FACS PI Buffer and filtered through a 40µm cell strainer into a 12 x 75mm tube. The cells are kept in the dark
at 4°C until cell sorting.
12.  Controls for setting up the flow cytometer can be prepared using an aliquot of CD235a
- LDFL cells saved for this purpose.
Use about 2 x 10
5 cells per staining. On overview of the controls needed, as well as the sort itself, are shown in the table
below. Samples #1 and #5 are not strictly necessary, but are nonetheless useful. Cells for sample #1 can be added directly
to 0.5mL of FACS PI buffer in a 12 x 75mm tube and held at 4°C until needed. Add the cells for samples #2-5 in a
volume of 10-50µl blocking buffer into 96-well V-bottom plates. Incubate the cells together with the indicated volume of
labeled antibody on ice for at least 30 minutes. Add 200µl of FACS washing buffer and centrifuge for 3 minutes at 300X
g at 4°C. Discard the supernatant by quickly inverting the plate, leaving the pelleted cells behind in the plate. Repeat the
washing procedure with 250µl of FACS washing buffer, suspending the pelleted cells with the addition of the washing
buffer. Suspend the washed samples in 0.5mL of FACS PI Buffer. Dispense the cells into 1.2mL microtiter for analysis.
These microtiter can be placed inside the larger 12 x 75 mm tubes, which fit the sample ports of flow cytometers.
Table 3:
Sample FITC PE APC PI
#1 Unstained none none none yes
#2 Isotype Control IgG1 (5µl) IgG1 (5µl) IgG1 (10µl) yes
#3 FITC Compensation CD34 (20µl) IgG1 (5µl) IgG1 (10µl) yes
#4 PE Compensation IgG1 (5µl) CD38 (10µl) IgG1 (10µl) yes
#5 APC Compensation IgG1 (5µl) IgG1 (5µl) CD34 (10µl) yes
#6 The Sort Lin panel CD38 CD34 yes
13.  Cells are sorted as shown in Fig. 1. Live cells are selected based on the lack of PI staining (region 1). Region 2 is set to
include cells with a low to moderate forward light scatter and low side light scatter profile. This gate can be adjusted by
gating on CD34
++ cells and examining the forward and side light-scatter properties of these cells. Any remaining Lin
+
cells are removed using region 3 to select Lin-FITC
- cells. The expression of CD34 and CD38 is viewed on cells found in
all three regions. Regions are drawn to isolate the desired subpopulations of progenitors. Sample #5 of the controls is
useful in defining lack of CD38 expression on CD34
++ cells. We define CD34
++ as the level of CD34 expression found on
CD38
- cells that express high levels of CD34. When isolating both CD38
-CD34
++Lin
- and CD38
+CD34
++Lin
- cells, the
goal is to obtain cells with the same level of CD34 expression. Regions need to be drawn conservatively as reanalysis of
the sorted cells invariable indicates a spread in the sorted cells from their original regions.
Protocol 2: Culture of colony-forming cells with erythroid, myeloid and lymphoid potential.
Reagents:
2X serum-deprived medium:
1.  Dissolve a 1L package of powdered Iscove's modified Dulbecco's medium (IMDM #12200, Life Technologies) in about
800mL of tissue culture grade (deionized) water.
2.  Stir in 3.024g of sodium bicarbonate (#S-4019, Sigma Chemical Company)Muench et al.
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3.  Add 40g of fraction-V ethanol-extracted BSA (#100 362, Boehringer Mannheim Biochemicals, http://www.boehringer-
mannheim.com) to the surface of the medium and let the BSA dissolve without stirring. This step will take about 1-2
hours.
4.  Add 400mg of human iron-saturated (holo) transferrin (#82-349-1, Serologicals Proteins Inc., Kankakee, IL).
5.  Add 20mg of recombinant human insulin (#1376 497, Boehringer Mannheim Biochemicals). Stock aliquots of 10mg/ml
are stored at -80°C.
6.  Add 650µl of a 1% solution of α-thioglycerol (#M-6145, Sigma Chemical Company). Use freshly prepared 1%
α-thioglycerol made by adding 100µl to 9.9mL of water or PBS.
7.  Add deionized water to 1L.
8.  Sterile filter and store at 4°C or freeze at aliquots at -20°C for long-term storage.
2.4% (2X) methylcellulose:
1.  1) Sterilize 500mL of tissue culture grade water in a large (2L) flask with a large magnetic stir bar inside the flask.
2.  Sterilize 24g of 4000 centipoises methylcellulose (#M0512, Sigma Chemical Company) in a 500mL beaker.
3.  Carefully remove the flask containing the water from the autoclave while still hot. Transfer the flask to a heated stir plate
that is set up inside a laminar flow hood. Bring the water to a boil and slowly add the methylcellulose powder. Exercise
caution as addition of the methylcellulose will cause the boiling water to foam and possibly spill out of the flask. Addition
of the methylcellulose may take 15 to 30 minutes.
4.  Turn off the heater and allow the methylcellulose suspension to stir and cool to =37°C. This may take a over an hour.
5.  Prepare 500mL 2X IMDM by dissolving a 1L package of IMDM and adding 3.024g sodium bicarbonate and 650µl of a
1% solution of a-thioglycerol, prepared as described above.
6.  Once the methylcellulose solution has cooled sufficiently, add the 2X IMDM. Make sure the flask is well covered with
foil to keep the contents sterile and transfer the flask to a stir plate at 4°C. Stir vigorously overnight. At some point during
the mixing process the methylcellulose will dissolve and the increased viscosity of the solution will prevent further
stirring.
7.  Aliquot the 2X methylcellulose solution by pouring approximately 40mL into 50mL polypropylene tubes. Aliquots can be
kept frozen for at least a year at -20°C.
Cytokines. Cytokines are available from R&D Systems, Inc. (Minneapolis, MN, http://www.rndsystems.com) or from PeproTech
Inc. (Rocky Hill, NJ, http://www.peprotech.com). Cytokines are diluted in IMDM with 2% BSA and 50µg/ml gentamicin at 100X
final concentration and stored in 1mL aliquots at -80°C.
Table 4:
Cytokine Concentration used Product #/Source
EPO 10Units/ml 287-TC / R&D Systems
FL 100ng/ml 300-19 / PeproTech
GM-CSF 20ng/ml 215-GM / R&D Systems
IL-15 20ng/ml 247-IL / R&D Systems
SCF 50ng/ml 255-SC / R&D Systems
TPO 20ng/ml 288-TP / R&D SystemsMuench et al.
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Human low density lipoprotein (LDL). (#L-2139, Sigma Chemical Company).
Gentamicin sulfate (50mg/mL). (Life Technologies)
Protocol:
1.  Suspend cells in 2X serum-deprived medium. Cells should be plated a low cell concentration (e.g. 50 cells/plate for fetal
progenitors) such that fewer than 20 colonies develop/dish. Preliminary experiments to determine the optimal cell number
for plating may be required when the concentration of CFCs is not known.
2.  The final concentrations of all the components are as follows: 1X serum-deprived medium, 1.2% methylcellulose,
50µg/mL gentamicin, 20µg-protein/mL LDL, cytokines (concentrations as listed above) and the appropriate cell
concentration. The components are mixed in the following order in 50mL tube: 2X serum-deprived medium (final volume
less the other components), cells (volume variable with concentration), cytokines (10µL/mL), gentamicin (1µL/mL), LDL
(volume variable with product lot) and then 2X methylcellulose (half final volume). Mix the liquid components well
before adding the 2X methylcellulose. Measure and dispense the 2X methylcellulose using a syringe without a needle.
Vigorously mix the final solution. Let stand for a few minutes to allow air-bubbles to rise.
3.  Dispense 1mL of the final solution into the tissue culture dishes using a syringe with a 16 gauge needle. Disperse the
medium by tipping the plates back and forth. Place the plates into a larger petri dish or a sealed chamber with a dish full of
sterile water.
4.  Culture at 37°C in a fully humidified atmosphere consisting of 5% CO2 in air for 3 weeks. Mature progenitors, expressing
low levels of CD34, may require less time in culture to mature.
Protocol 3: Detection of CFCs with erythroid, myeloid and lymphoid potential.
Reagents:
Blocking Buffer. (see protocol 1)
FACS washing buffer. (see protocol 1)
FACS PI buffer. (see protocol 1)
mAbs:
Table 5:
Specificity-Label Clone Product # Isotype Source
CD1a-PE T6 IM1942 IgG Beckman-Coulter Inc.
CD14-APC M5E2 555399 IgG2a BD Biosciences
CD15-APC HI98 551376 IgM BD Biosciences
CD56-FITC C5.9 0562 IgG2b Exalpha Inc., Boston, MA
Disposable plasticware: 60 x 15mm culture dish with a 2mm grid (#25011 Corning Inc., Corning, NY,
http://www.scienceproducts.corning.com), non-sterile 96-well V-bottom plate (Costar Serocluster 96 #3897, Corning Inc.), 1.2mL
microtiter tubes.
Protocol:
1.  Prepare a solution of 10mL blocking buffer containing 250µl anti-CD1a-PE, 250µl anti-CD14-APC, 250µl anti-CD15-
APC and 250µL anti-CD56-FITC mAbs. Dispense 100µL/well of a 96-well plate (more or less may be used depending on
the number of colonies to be analyzed). Staining with these markers will be used to determine the presence of dendriticMuench et al.
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(CD1a
+CD14
+/-) myeloid (CD14
+ and/or CD15
+ cells) and NK cells (CD56
+ cells) within the individual colonies. The
plate is kept on ice in an ice bucket for easy access while scoring the culture dishes.
2.  Colonies are scored with the aid of a dissecting microscope. Placement of the culture dishes on an inverted culture dish
with a 2mm grid is useful in scoring the cultures and estimating the size of the colonies. A written log is kept of the
visibly observed properties of the colonies such as size and the presence of erythrocytes. Erythrocytes are identified
visually by the presence of hemoglobinized cells. Alternatively, erythrocytes can be identified by flow cytometry after
staining with labeled CD235a mAb. However, the number of parameters that can be measured flow cytometrically is
limited and erythrocytes are easily identified visually. Individual colonies are plucked using a 200µL pipette. This is best
accomplished by loading a clean pipette tip with about 20µL of the blocking buffer/mAb solution, with the pipette set for
150µL, and then harvesting the colony from the semi-solid medium. The colony is harvested while under visual inspection
using the microscope. Care is taken to harvest as much of the colony as possible without acquiring cells from a nearby
colony. The cells are dispersed in the blocking buffer/mAb solution remaining in the well. The preloaded solution helps to
push the cells and methylcellulose out of the pipette tip, but repeated pipetting is recommended to completely flush the
pipette tip. The position of individual colonies in the 96-well plate is recorded to later correlate the visual and flow
cytometric observations. After the last colony has been harvested, the cells are left to stain at 4°C for at least 30 minutes in
the dark.
3.  The stained cells are washed once by adding 150µL of FACS washing buffer and centrifuged for 3 minutes at 300X g at
4°C. Discard the supernatant by quickly inverting the plate, leaving the pelleted cells behind in the plate. Suspend the
samples in 100µL of FACS PI Buffer. Dispense the cells into 1.2mL microtiter tubes in a rack with a 96-well format for
analysis. Use of a multichannel pipette and maintaining the 96-well format throughout the staining procedure facilitates
handling of a large number of samples. The microtiter tubes can be, in turn, placed inside a larger 12 x 75mm tube,
required by flow cytometers, immediately before analysis.
4.  Controls required to adjust the parameters of the flow cytometer can be obtained from either a small sample of cells
grown in liquid culture in parallel with the clonal cultures and/or from colonies grown in a spare culture dish. 1 x 10
3 cells
grown in 10mL of medium and cytokines will provide plenty of cells for all controls after 3 weeks of growth. Background
staining is determined by staining with the nonspecific labeled antibodies listed above. Compensation is performed with
cells stained individually with the FITC-, PE- and APC-labeled mAbs. Note that the frequency of NK cells generated is
low and use of another marker such as CD235a-FITC may make adjusting compensation for the FL-1 parameter easier.
There are minor differences in the size and autofluorescence of cells grown in liquid culture and cells grown in semi-solid
cultures. For this reason, we routinely stain one large multilineage (erythroid-myeloid) colony with the non-specific
labeled antibodies as a control for determining the placement of regions in the analysis of the flow cytometric data.
5.  Data is collected based on time rather than event count such that a similar proportion of small and large colonies is
analyzed. Our flow cytometers are set to collect 60 seconds of data, which requires nearly the whole of the 100µL sample.
We define the presence of a population based on the finding of at least 3 events above background.